Oxidative pathways as a drug target for the treatment of autism

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 12, 2010, Pages 1301-1310

  Villagonzalo, Kristi Ann ^a   Dodd, Seetal ^a   Dean, Olivia ^a,d   Gray, Kylie ^b   Tonge, Bruce ^b   Berk, Michael ^a,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ORYGEN RESEARCH CENTRE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

antioxidant treatment; autism; autistic disorder; oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALANINE; AMMONIA; ANTIOXIDANT; ASCORBIC ACID; BETAINE; BIOLOGICAL MARKER; CARNITINE; CARNOSINE; CERULOPLASMIN; CYSTEINE; FOLINIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEAVY METAL; HOMOCYSTEINE; LACTIC ACID; MECOBALAMIN; METHIONINE; PYRIDOXINE; PYRUVIC ACID; TRANSFERRIN;

AUTISM; BIOSIS; CERULOPLASMIN BLOOD LEVEL; CINAHL; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; ENZYME ACTIVITY; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; LIPID PEROXIDATION; MEDLINE; METHYLATION; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN BINDING; PSYCINFO; REVIEW; SOCIAL INTERACTION; TRANSFERRIN BLOOD LEVEL;

ANTIOXIDANTS; AUTISTIC DISORDER; BIOLOGICAL MARKERS; HUMANS; MOLECULAR TARGETED THERAPY; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 78249244490     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.528394     Document Type: Review

References (83)

1. Kogan MD, Strickland BB, Blumberg SJ, et al. A national profile of the health care experiences and family impact of autism spectrum disorder among children in the United States, 2005-2006. Pediatrics 2008;122(6):1149-58
2. Herring S, Gray K, Taffe J, et al. Behaviour and emotional problems in toddlers with pervasive developmental disorders and developmental delay: associations with parental mental health and family functioning. J Intellect Disabil Res 2006;50(12):874-82
3. Lecavalier L, Leone S, Wiltz J. The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. J Intellect Disabil Res 2006;50(3):172-83
4. Grindle CF, Kovshoff H, Hastings RP, Remington B. Parents' experiences of home-based applied behavior analysis programs for young children with autism. J Autism Dev Disord 2009;39(1):42-56
5. Santosh PJ, Baird G. Pharmacotherapy of target symptoms in autistic spectrum disorders. Indian J Pediatr 2001;68(5):427-31
6. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008;17(4):803-20
7. Green VA. Parental experience with treatments for autism. J Dev Phys Disabil 2007;19(2):91-101
8. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11(6):851-76
9. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3(3):205-14
10. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008;29(7):346-51 • A good review of glutathione, the brain's most important antioxidant and a potential therapeutic target.
11. Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 2002;67(5):341-3
12. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology 2006;13(3):171-81 •• A comprehensive review of the evidence for oxidative stress in autism.
13. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: cause or effect? Biochim Biophys Acta 2010;1797(6-7): 1130-7
14. Rezin GT, Amboni G, Zugno AI, et al. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 2009;34(6):1021-9
15. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80(6):1611-17
16. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48(2):137-52
17. James SJ, Melnyk S, Jernigan S, et al. Abnormal transmethylation/ transsulfuration metabolism and DNA hypomethylation among parents of children with autism. J Autism Dev Disord 2008;38(10):1966-76
18. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr 2009;89(1):425-30
19. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141(8):947-56
20. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - The antioxidant proteins. Life Sci 2004;75(21):2539-49
21. Weissman JR, Kelley RI, Bauman ML, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS One 2008;3(11): published online 26 November 2008, doi:10.1371/journal. pone.0003815
22. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol 2006;21(2):170-2
23. Oliveira G, Ataide A, Marques C, et al. Epidemiology of autism spectrum disorder in Portugal: prevalence, clinical characterization, and medical conditions. Dev Med Child Neurol 2007;49(10):726-33
24. Haas RH. Autism and mitochondrial disease. Dev Disabil Res Rev 2010;16(2):144-53
25. Clark-Taylor T, Clark-Taylor BE. Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase. Med Hypotheses 2004;62(6):970-5
26. Filipek PA, Juranek J, Nguyen MT, et al. Relative carnitine deficiency in autism. J Autism Dev Disord 2004;34(6):615-23
27. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005;47(3):185-9
28. Geier DA, Kern JK, Garver CR, et al. Biomarkers of environmental toxicity and susceptibility in autism. J Neurol Sci 2009;280(1-2): 101-8
29. Geier DA, Kern JK, Garver CR, et al. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 2009;34(2):386-93
30. Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 2006;66(4):182-8
31. Adams JB, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altern Complement Med 2006;12(1):59-63
32. Main P A E, Angley MT, Thomas P, et al. Folate and methionine metabolism in autism: a systematic review. Am J Clin Nutr 2010;91(6):1598-620
33. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health 2006;9(6):485-99 • A thorough review of the evidence for the role of glutathione in the pathophysiology of autism.
34. Sen CK. Nutritional biochemistry of cellular glutathione. J Nutr Biochem 1997;8(12):660-72
35. Cohly H H P, Panja A. Immunological findings in autism. Int Rev Neurobiol 2005;71:317-41
36. Molloy CA, Manning-Courtney P. Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism 2003;7(2):165-71
37. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem 2009;42(10-11): 1032-40
38. Zoroglu SS, Armutcu F, Ozen S, et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatr Clin Neurosci 2004;254(3):143-7
39. Ming X, Stein TP, Brimacombe M, et al. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005;73(5):379-84
40. Sogut S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003;331(1-2): 111-17
41. Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993;17(5):765-74
42. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 2004;10(6):1033-9
43. Kern JK, Grannemann BD, Trivedi MH, Adams JB. Sulfhydryl-reactive metals in autism. J Toxicol Environ Health A 2007;70(8):715-21
44. Quig D. Cysteine metabolism and metal toxicity. Altern Med Rev 1998;3(4):262-70
45. Mutter J, Naumann J, Schneider R, et al. Mercury and autism: accelerating evidence? Neuroendocrinol Lett 2005;26(5):439-46
46. Ballatori N, Clarkson TW. Biliary secretion of glutathione and of glutathione-metal complexes. Fundam Appl Toxicol 1985;5(5):816-31
47. Chauhan A, Sheikh AM, Chauhan V. Increased copper-mediated oxidation of membrane phosphatidylethanolamine in autism. Am J Biochem Biotechnol 2008;4(2):95-100
48. Adams M, Lucock M, Stuart J, et al. Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion-DHFR in occurrence of autism. Neurosci Lett 2007;422(1):24-9
49. Buyske S, Williams TA, Mars AE, et al. Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism. BMC Genetics 2006;7:8
50. Serajee FJ, Nabi R, Zhong H, Huq A H M M. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol 2004;19(6):413-17
51. Ming X, Johnson WG, Stenroos ES, et al. Genetic variant of glutathione peroxidase 1 in autism. Brain Dev 2010;32(2):105-9
52. Lepagnol-Bestel AM, Maussion G, Boda B, et al. SLC25A12 expression is associated with neurite outgrowth and is upregulated in the prefrontal cortex of autistic subjects. Mol Psychiatry 2008;13(4):385-97
53. Filipek PA, Juranek J, Smith M, et al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003;53(6):801-4
54. Palmieri L, Papaleo V, Porcelli V, et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 2010;15(1):38-52
55. Bertoglio K, James SJ, Deprey L, et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med 2010;16(5):555-60
56. Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 2005;12(20):2293-315
57. Hipkiss AR. Could carnosine or related structures suppress Alzheimer's disease? J Alzheimers Dis 2007;11(2):229-40
58. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002;17(11):833-7
59. Dodd S, Dean O, Copolov DL, et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008;8(12):1955-62
60. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64(5):361-8
61. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64(6):468-75
62. Berk M, Munib A, Dean O, et al. Qualitative methods in early-phase drug trials: data and methods from a trial of N-acetyl cysteine in schizophrenia. J Clin Psychiatry 2010; published online 21 September 2010 doi:10.4088/JCP. 09m05741yel
63. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010;23(2):103-10
64. Deth R, Muratore C, Benzecry J, et al. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008;29(1):190-201 •• This paper proposes a mechanism whereby oxidative stress relates to the symptomatology of autism.
65. Dawson G. Early behavioral intervention, brain plasticity, and the prevention of autism spectrum disorder. Dev Psychopathology 2008;20(3):775-803
66. Bodfish JW. Treating the core features of autism: are we there yet? Ment Retard Dev Disabil Res Rev 2004;10(4):318-26 • A comprehensive review of the current state of autism treatment.
67. Howlin P, Magiati I, Charman T. Systematic review of early intensive behavioral interventions for children with autism. Am J Intellect Dev Disabil 2009;114(1):23-41
68. Green VA, Pituch KA, Itchon J, et al. Internet survey of treatments used by parents of children with autism. Res Dev Disabil 2006;27(1):70-84
69. Lynch ME. A report of the parent initiated use of dietary interventions and nutritional supplements as a treatment for individuals with an autism spectrum disorder. Int J Disabil Commun Rehabil 2004;3(4):1-17
70. Virues-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev 2010;30(4):387-99
71. Makrygianni MK, Reed P. A meta-analytic review of the effectiveness of behavioural early intervention programs for children with autistic spectrum disorders. Res Autism Spectrum Disord 2010;4(4):577-93
72. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics 2010;125(1):17-23
73. Witwer A, Lecavalier L. Treatment rates and patterns in young people with autism spectrum disorders. J Child Adolesc Psychopharmacol 2005;15(4):671-81
74. Matson JL, Dempsey T. Autism spectrum disorders: pharmacotherapy for challenging behaviors. J Dev Phys Disabil 2008;20(2):175-91
75. Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007;8(11):1579-603
76. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21(6):450-5
77. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30(3):582-9
78. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53(11):1001-8
79. Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 2007;37(4):628-36
80. Rossignol DA, Rossignol LW, James SJ, et al. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatrics 2007;7:36
81. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A - medical results. BMC Clin Pharmacol 2009;9:16
82. Sinha Y, Silove N, Williams K. Chelation therapy and autism. Br Med J 2006;333(7571):756
83. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33(9):2187-99